Announced details
Treatment of acute spinal cord injury and severe cervical spinal cord injury
The Society will present analysis results from clinical trials conducted by the Company.
The 55th Annual Meeting of the Japanese Society for Spine Surgery and Related Research will be held from 16 April to 18 April 2026 at the Fukuoka International Congress Center and Marine Messe Fukuoka Hall B. Other attributes: Not disclosed
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
Miyakoshi N et al. Spinal Cord 2021 Jun;59(6):626-634.；Shingu Hikosuke (新宮彦助), “Prevention of Spinal Cord Injury,” Japanese Journal of Paraplegia 13:48-49, 2000；Sakai Hiroaki (坂井宏旭), “Epidemiological Survey,” Sogo Rehabilitation 36:969-972, 2008
| Item | Details |
|---|---|
| Names of Products / Services Covered | Recombinant human HGF protein product (development code: KP-100IT) |
| Counterparty | Japanese Society for Spine Surgery and Related Research (55th Annual Meeting of the Japanese Society for Spine Surgery and Related Research) |
| Counterparty overview | The 55th Annual Meeting of the Japanese Society for Spine Surgery and Related Research will be held from 16 April to 18 April 2026 at the Fukuoka International Congress Center and Marine Messe Fukuoka Hall B. Other attributes: Not disclosed |
| Relationship with the Company | The Society will present analysis results from clinical trials conducted by the Company. |
| Applicable area | Treatment of acute spinal cord injury and severe cervical spinal cord injury |
| Source | Miyakoshi N et al. Spinal Cord 2021 Jun;59(6):626-634.；Shingu Hikosuke (新宮彦助), “Prevention of Spinal Cord Injury,” Japanese Journal of Paraplegia 13:48-49, 2000；Sakai Hiroaki (坂井宏旭), “Epidemiological Survey,” Sogo Rehabilitation 36:969-972, 2008 |
Items this document does not state (12)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To provide more comprehensive insights into the efficacy and clinical positioning of HGF therapy for severe cervical spinal cord injury through comparison and discussion of the post hoc analysis results from the Phase III trial and the results of the Phase I/II trial.